AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21940213 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (5 sets of 4 repetitions with 3 min inter-set rest)
Number of subjects: 14
Study 21940213 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (5 sets of 4 repetitions with 20 s inter-set rest)
Number of subjects: 14
Study 20581575 — intervention group
Group type: COMPARATOR
Intervention: Randomized phase II trial designs
Number of subjects: 0
Study 17378454 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick intermediate layer of resin-based composite (RBC)
Number of subjects: 12
Study 17378454 — intervention group
Group type: COMPARATOR
Intervention: Control group (without RBC)
Number of subjects: 12
Study 15564275 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a local-authority exercise referral scheme and written information
Number of subjects: 545
Study 15564275 — intervention group
Group type: COMPARATOR
Intervention: Written information only (Control)
Number of subjects: 545
Study 12392583 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg
Number of subjects: 46
Study 12392583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 9915276 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneoscopic technique
Number of subjects: 148
Study 9915276 — intervention group
Group type: COMPARATOR
Intervention: Surgical technique
Number of subjects: 148
Study 7561435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin prophylaxis (n = 52)
Number of subjects: 103
Study 7561435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin prophylaxis (2 g intravenously, n = 25)
Number of subjects: 103
Study 7561435 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (n = 26)
Number of subjects: 103
Study 7561435 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results from both studies
Number of subjects: 103
Study 7561435 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative bacteriology sample
Number of subjects: 103
Study 7561435 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound complications
Number of subjects: 103
Study 7561435 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative presence of bacteria
Number of subjects: 103
Study 7561435 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobe isolates preoperatively
Number of subjects: 103
Study 7561435 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobes cultured postoperatively
Number of subjects: 103
Study 2405197 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 444
Study 2405197 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 444
Study 7382709 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy and surgery
Number of subjects: 298
Study 7382709 — intervention group
Group type: COMPARATOR
Intervention: Surgery and postoperative radiation therapy
Number of subjects: 298
Study 7382709 — intervention group
Group type: COMPARATOR
Intervention: Surgery and postoperative radiation therapy plus radical radiation therapy (for oral cavity and oropharynx lesions)
Number of subjects: 298
Study 31765664 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric cycling (ECC)
Number of subjects: 24
Study 31765664 — intervention group
Group type: COMPARATOR
Intervention: Concentric cycling (CON)
Number of subjects: 24
Study 31412242 — intervention group
Group type: COMPARATOR
Intervention: Nicotinamide riboside (NR) 1 g per day for 21 days
Number of subjects: 12
Study 28978802 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever live‐attenuated vaccine (YFLAV)
Number of subjects: 68
Study 25457173 — intervention group
Group type: EXPERIMENTAL
Intervention: Transillumination method using Trachlight
Number of subjects: 80
Study 25457173 — intervention group
Group type: COMPARATOR
Intervention: Main-stem method
Number of subjects: 80
Study 25457173 — intervention group
Group type: EXPERIMENTAL
Intervention: Transillumination method
Number of subjects: 80
Study 23761087 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX implant 0.70 mg
Number of subjects: 229
Study 23761087 — intervention group
Group type: COMPARATOR
Intervention: DEX implant 0.35 mg
Number of subjects: 229
Study 23761087 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 229
Study 21041105 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-6-glucuronide (M6G)
Number of subjects: 517
Study 21041105 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 517
Study 20168099 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 2 x 5 mg (5 mg intravenously at randomization and at month 12)
Number of subjects: 0
Study 20168099 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 1 x 5 mg (5 mg intravenously at randomization and placebo at month 12)
Number of subjects: 0
Study 20168099 — intervention group
Group type: COMPARATOR
Intervention: Placebo (at randomization and at month 12)
Number of subjects: 0
Study 20168099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both zoledronic acid regimens
Number of subjects: 0
Study 17935572 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily infant probiotic supplement for the first 6 months of life
Number of subjects: 0
Study 17935572 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15453623 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzydamine hydrochloride 3% cream
Number of subjects: 0
Study 15453623 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study 11565814 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 0
Study 11565814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study 11565814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9389780 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol gel (1.0 mg of oestradiol daily, Divigel/Sandrena)
Number of subjects: 120
Study 9389780 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol delivering patch (50 micrograms oestradiol/24 h, Estraderm TTS)
Number of subjects: 120
Study 9389780 — intervention group
Group type: COMPARATOR
Intervention: Reference group (25 women without HRT)
Number of subjects: 120
Study 8238177 — intervention group
Group type: EXPERIMENTAL
Intervention: ST waveform plus cardiotocogram
Number of subjects: 2434
Study 8238177 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiotocogram
Number of subjects: 2434
Study 3476718 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% strontium chloride hexahydrate dentifrice
Number of subjects: 61
Study 3476718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 29618017 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly practice for 6 months
Number of subjects: 49
Study 29618017 — intervention group
Group type: COMPARATOR
Intervention: Three consecutive practices at 3, 5 and 6 months
Number of subjects: 49
Study 29618017 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians
Number of subjects: 49
Study 29618017 — intervention group
Group type: COMPARATOR
Intervention: Nurses
Number of subjects: 49
Study 26365335 — intervention group
Group type: EXPERIMENTAL
Intervention: S05985 (perindopril 5 mg and amlodipine 5 mg)
Number of subjects: 30
Study 26365335 — intervention group
Group type: COMPARATOR
Intervention: Perindopril tert‐butylamine 4 mg
Number of subjects: 30
Study 26365335 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 30
Study 24216317 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin preloading (80 mg 12 h and 40 mg 2 h pre-PCI)
Number of subjects: 499
Study 24216317 — intervention group
Group type: COMPARATOR
Intervention: Usual care (atorvastatin 40 mg/day)
Number of subjects: 499
Study 24216317 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin preloading
Number of subjects: 499
Study 24216317 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 499
Study 23787061 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness in Schools Programme
Number of subjects: 522
Study 23787061 — intervention group
Group type: COMPARATOR
Intervention: Usual school curriculum
Number of subjects: 522
Study 20118154 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCI with postconditioning
Number of subjects: 118
Study 20118154 — intervention group
Group type: COMPARATOR
Intervention: Conventional PPCI
Number of subjects: 118
Study 18678958 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (100‐Hz, 450‐microsecond pulses for 5 minutes in a 3‐seconds‐on 3‐seconds‐off duty cycle)
Number of subjects: 7
Study 18678958 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A
Number of subjects: 7
Study 18678958 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (60‐Hz, 250‐microsecond pulses for 5 minutes in a 10‐seconds‐on 20‐seconds‐off duty cycle)
Number of subjects: 7
Study 16618403 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 weeks of peginterferon-alfa-2a (180 microg/wk) plus ribavirin (800 mg/day)
Number of subjects: 455
Study 16618403 — intervention group
Group type: COMPARATOR
Intervention: 72 weeks of peginterferon-alfa-2a (180 microg/wk) plus ribavirin (800 mg/day)
Number of subjects: 455
Study 16618403 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 weeks of treatment for patients HCV-RNA positive at week 12
Number of subjects: 455
Study 14563580 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated protein C (APC) at 0.06 mg/kg per day
Number of subjects: 19
Study 14563580 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin at 100 to 400 U/kg per day
Number of subjects: 19
Study 14563580 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 19
Study 14563580 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated protein C (APC)
Number of subjects: 19
Study 11459333 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg/day titrated to a maximum of 20 mg/day)
Number of subjects: 15
Study 11459333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9205772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordaflex 20 mg retard filmtablet
Number of subjects: 31
Study 9205772 — intervention group
Group type: COMPARATOR
Intervention: Control preparation (not specified)
Number of subjects: 31
Study 7962316 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopregnanolone
Number of subjects: 27
Study 7962316 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnanolone
Number of subjects: 27
Study 7962316 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 27
Study 7962316 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopregnanolone to Progesterone ratio
Number of subjects: 27
Study 7962316 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnanolone to Progesterone ratio
Number of subjects: 27
Study 7962316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of Allopregnanolone and Pregnanolone to Progesterone ratio
Number of subjects: 27
Study 7962316 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations with plasma progesterone levels
Number of subjects: 27
Study 7962316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood and behavioral symptoms correlation
Number of subjects: 27
Study 3677542 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 240 mg
Number of subjects: 30
Study 3677542 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 120 mg
Number of subjects: 30
Study 3677542 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine (n=10)
Number of subjects: 30
Study 3677542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=5)
Number of subjects: 30
Study 30020317 — intervention group
Group type: EXPERIMENTAL
Intervention: Video assisted training (VAT)
Number of subjects: 12
Study 28039902 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 214
Study 25936312 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein apheresis
Number of subjects: 0
Study 25936312 — intervention group
Group type: COMPARATOR
Intervention: Sham apheresis
Number of subjects: 0
Study 22318691 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid smoking (SS)
Number of subjects: 161
Study 21659315 — intervention group
Group type: EXPERIMENTAL
Intervention: mQLAZT (modified quarter laser-assisted zona thinning)
Number of subjects: 647
Study 18479977 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative methods including interviews, focus groups, audio-recording recruitment interactions, and feedback sessions for RCT staff.
Number of subjects: 5
Study 18479977 — intervention group
Group type: COMPARATOR
Intervention: ProtecT qualitative methods
Number of subjects: 5
Study 16476149 — intervention group
Group type: EXPERIMENTAL
Intervention: T allele of G protein beta3 (GNbeta3)
Number of subjects: 0
Study 16476149 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline personality disorder
Number of subjects: 0
Study 16476149 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood sexual abuse
Number of subjects: 0
Study 16476149 — intervention group
Group type: EXPERIMENTAL
Intervention: Young depressed patients
Number of subjects: 0
Study 12895329 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone
Number of subjects: 3030
Study 12895329 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg mifepristone
Number of subjects: 3030
Study 12895329 — intervention group
Group type: COMPARATOR
Intervention: Both doses of mifepristone
Number of subjects: 3030
Study 10813501 — intervention group
Group type: EXPERIMENTAL
Intervention: S. haematobium infection
Number of subjects: 7710
Study 10813501 — intervention group
Group type: EXPERIMENTAL
Intervention: S. mansoni infection
Number of subjects: 7710
Study 10813501 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive uropathy
Number of subjects: 7710
Study 10813501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-detected bladder lesions
Number of subjects: 7710
Study 10813501 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatomegaly, splenomegaly, and periportal fibrosis (PPF)
Number of subjects: 7710
Study 9197351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment group (15 mg/kg/day)
Number of subjects: 102
Study 9197351 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 102
Study 31160805 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block combined with subcutaneous perineal anaesthesia and intrarectal lidocaine gel
Number of subjects: 216
Study 31160805 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anaesthesia
Number of subjects: 216
Study 30756393 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration cryoballoon application (105 seconds)
Number of subjects: 222
Study 30756393 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium duration cryoballoon application (164 seconds)
Number of subjects: 222
Study 30756393 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration cryoballoon application (224 seconds)
Number of subjects: 222
Study 28062082 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention model (n=30)
Number of subjects: 60
Study 28062082 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control group, n=30)
Number of subjects: 60
Study 26604652 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 35
Study 26604652 — intervention group
Group type: COMPARATOR
Intervention: Control group (patient controlled intravenous analgesia)
Number of subjects: 35
Study 23179591 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire distribution (Study 1)
Number of subjects: 10000
Study 23179591 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire distribution (Study 2)
Number of subjects: 10000
Study 23179591 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire distribution (Study 3)
Number of subjects: 10000
Study 23179591 — intervention group
Group type: COMPARATOR
Intervention: Control group (Study 1)
Number of subjects: 10000
Study 23179591 — intervention group
Group type: COMPARATOR
Intervention: Control group (Study 2)
Number of subjects: 10000
Study 21600087 — intervention group
Group type: EXPERIMENTAL
Intervention: Antofloxacin hydrochloride tablet
Number of subjects: 719
Study 21600087 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin tablet
Number of subjects: 719
Study 18716482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary rehabilitation (Rehab)
Number of subjects: 56
Study 15686288 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained raters
Number of subjects: 24
Study 15686288 — intervention group
Group type: COMPARATOR
Intervention: Untrained raters
Number of subjects: 24
Study 12868802 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 every 3 weeks for four cycles
Number of subjects: 162
Study 12868802 — intervention group
Group type: COMPARATOR
Intervention: CVAP (Control)
Number of subjects: 162
Study 10470596 — intervention group
Group type: EXPERIMENTAL
Intervention: Amtolmetin guacyl 600 mg bid
Number of subjects: 64
Study 10470596 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg tid
Number of subjects: 64
Study 9112714 — intervention group
Group type: EXPERIMENTAL
Intervention: Health services utilization for low back pain in Quebec
Number of subjects: 2147
Study 9112714 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized imaging techniques
Number of subjects: 2147
Study 9112714 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 2147
Study 9112714 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial specific diagnosis and proximity to a university hospital
Number of subjects: 2147
Study 9112714 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to specialists
Number of subjects: 2147
Study 1928685 — intervention group
Group type: EXPERIMENTAL
Intervention: Verrill technique
Number of subjects: 48
Study 1928685 — intervention group
Group type: COMPARATOR
Intervention: Glasgow Dental Hospital technique
Number of subjects: 48
Study 1928685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 48
Study 7041522 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (0.5 micrograms daily)
Number of subjects: 58
Study 7041522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 30621673 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention (D-group)
Number of subjects: 110
Study 30621673 — intervention group
Group type: COMPARATOR
Intervention: Control (C-group)
Number of subjects: 110
Study 30621673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 110
Study 28372661 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 150
Study 28372661 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 150
Study 28372661 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 150
Study 26545203 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium longum subsp. infantis
Number of subjects: 24
Study 26545203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24572293 — intervention group
Group type: EXPERIMENTAL
Intervention: G207 (oncolytic HSV-1)
Number of subjects: 9
Study 24572293 — intervention group
Group type: EXPERIMENTAL
Intervention: G207 (oncolytic HSV-1) + 5 Gy radiation
Number of subjects: 9
Study 22828022 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at true points (third eye and Shen men)
Number of subjects: 70
Study 22828022 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure at sham points
Number of subjects: 70
Study 19660001 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic A
Number of subjects: 24
Study 19660001 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic B
Number of subjects: 24
Study 19660001 — intervention group
Group type: COMPARATOR
Intervention: Branded amoxicillin
Number of subjects: 24
Study 17551492 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative patients
Number of subjects: 0
Study 17551492 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy or adjuvant combined chemo-radiotherapy
Number of subjects: 0
Study 17551492 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 17551492 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment groups (adjuvant therapy)
Number of subjects: 0
Study 15292307 — intervention group
Group type: EXPERIMENTAL
Intervention: Jugular venous sampling (JVS)
Number of subjects: 88
Study 15292307 — intervention group
Group type: COMPARATOR
Intervention: Inferior petrosal sinus sampling (IPSS)
Number of subjects: 88
Study 11472320 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with ranitidine (300 mg), amoxicillin (1000 mg), and clarithromycin (500 mg) for 7 days
Number of subjects: 129
Study 11472320 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 129
Study 11472320 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 129
Study 9493257 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive treatment A
Number of subjects: 0
Study 9493257 — intervention group
Group type: COMPARATOR
Intervention: Anti-hypertensive treatment B
Number of subjects: 0
Study 7931701 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.65 mg)
Number of subjects: 100
Study 7931701 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B‐12 (0.4 mg)
Number of subjects: 100
Study 7931701 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B‐6 (10 mg)
Number of subjects: 100
Study 7931701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of folic acid, vitamin B‐12, and vitamin B‐6
Number of subjects: 100
Study 7931701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3348139 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) oral spray
Number of subjects: 10
Study 3348139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31121013 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine (DOR) 100 mg
Number of subjects: 0